{"id":"fluad-vaccine","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Injection site pain or erythema"},{"rate":"10–20","effect":"Myalgia"},{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"5–10","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluad contains inactivated influenza virus antigens that trigger both humoral and cellular immune responses, enabling the body to recognize and neutralize circulating influenza viruses. The vaccine is formulated with an adjuvant (MF59) to enhance immunogenicity, particularly in older adults and immunocompromised populations. This approach provides protection against seasonal influenza infection and reduces severity of disease if breakthrough infection occurs.","oneSentence":"Fluad is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:52.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults aged 18 years and older"}]},"trialDetails":[{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT05291676","phase":"PHASE2","title":"Systems Investigation of Vaccine Responses in Aging and Frailty","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Influenza","enrollment":96},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT05110911","phase":"","title":"Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-04-02","conditions":"Influenza, Human, SARS-CoV-2 Infection","enrollment":1500},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT02871206","phase":"PHASE4","title":"Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-11","conditions":"Influenza","enrollment":3425},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05518500","phase":"PHASE4","title":"A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults","status":"RECRUITING","sponsor":"The Jackson Laboratory","startDate":"2022-08-31","conditions":"Aging, Influenza Vaccine, Dendritic Cell","enrollment":75},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT03694808","phase":"PHASE4","title":"FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care","status":"COMPLETED","sponsor":"David H. Canaday","startDate":"2018-09-23","conditions":"Flu","enrollment":478},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT02529904","phase":"PHASE2","title":"ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Influenza","enrollment":120},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT03603509","phase":"PHASE4","title":"Gene Signatures of Influenza Vaccine Responses in Older Adults","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-08-27","conditions":"Influenza","enrollment":241},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT02882100","phase":"PHASE4","title":"Adjuvanted Influenza Vaccination in U.S. Nursing Homes","status":"COMPLETED","sponsor":"Insight Therapeutics, LLC","startDate":"2016-04","conditions":"Influenza, Influenza-like Illness","enrollment":823},{"nctId":"NCT02523287","phase":"PHASE4","title":"Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-10-02","conditions":"Safety Markers of Adjuvanted Influenza Vaccine","enrollment":240},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT03183908","phase":"PHASE4","title":"FLUAD® vs. Fluzone® High-Dose Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-28","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":757},{"nctId":"NCT02933723","phase":"NA","title":"Immunogenicity of Influenza Vaccine in Long Term Care","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2016-10","conditions":"Influenza","enrollment":200},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT01222403","phase":"PHASE4","title":"A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Influenza","enrollment":767},{"nctId":"NCT00319098","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Influenza","enrollment":5075},{"nctId":"NCT00363077","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-02","conditions":"Influenza","enrollment":150},{"nctId":"NCT01682369","phase":"PHASE2","title":"ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-09","conditions":"Influenza","enrollment":90},{"nctId":"NCT02362919","phase":"","title":"Influenza Vaccination Among the Elderly Individuals","status":"COMPLETED","sponsor":"Helmholtz Centre for Infection Research","startDate":"2015-02","conditions":"Influenza","enrollment":200},{"nctId":"NCT02560909","phase":"PHASE4","title":"Adjuvanted Influenza Vaccine in Stem Cell Transplant","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-10","conditions":"Transplantation, Influenza Vaccines","enrollment":73},{"nctId":"NCT00478816","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-05","conditions":"Prophylaxis of Avian Influenza Vaccine","enrollment":58},{"nctId":"NCT00522067","phase":"PHASE2","title":"Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-06","conditions":"Influenza Disease","enrollment":52},{"nctId":"NCT02686398","phase":"PHASE4","title":"Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-10","conditions":"Influenza, End Stage Renal Failure, Chronic Kidney Disease","enrollment":174},{"nctId":"NCT00734734","phase":"PHASE2","title":"Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Interpandemic Influenza","enrollment":64},{"nctId":"NCT00956761","phase":"PHASE2","title":"Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Seasonal Influenza","enrollment":63},{"nctId":"NCT00644059","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Influenza, Human","enrollment":4902},{"nctId":"NCT02368327","phase":"NA","title":"Gene Expression Profiles in Muscle After Immunisation","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2015-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT01368796","phase":"PHASE4","title":"Comparison of 4 Influenza Vaccines in Seniors","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-07","conditions":"Influenza Vaccine","enrollment":953},{"nctId":"NCT02215863","phase":"PHASE4","title":"Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2014-09","conditions":"Influenza, Streptococcus Pneumoniae","enrollment":1195},{"nctId":"NCT01346592","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Influenza Disease","enrollment":6104},{"nctId":"NCT01771367","phase":"NA","title":"Training Study to Characterize Biomarkers to Flu Vaccines","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2013-01","conditions":"Healthy","enrollment":49},{"nctId":"NCT02225327","phase":"PHASE4","title":"MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224},{"nctId":"NCT01162122","phase":"PHASE3","title":"Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-08","conditions":"Influenza","enrollment":7109},{"nctId":"NCT01651104","phase":"PHASE2","title":"Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT01879540","phase":"PHASE2","title":"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT01819155","phase":"PHASE2","title":"Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa","status":"COMPLETED","sponsor":"PATH","startDate":"2013-04","conditions":"Influenza","enrollment":296},{"nctId":"NCT01032395","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-03","conditions":"H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease","enrollment":342},{"nctId":"NCT01258023","phase":"PHASE2","title":"Seasonal Flu Vaccine in Adult Transplant Recipients","status":"COMPLETED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2010-11","conditions":"Immunocompromised, Transplanted","enrollment":122},{"nctId":"NCT00522236","phase":"PHASE2","title":"Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-06","conditions":"Influenza","enrollment":56},{"nctId":"NCT00984945","phase":"PHASE1","title":"Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2009-09","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":48},{"nctId":"NCT01119157","phase":"PHASE4","title":"Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines","status":"UNKNOWN","sponsor":"National Centre for Epidemiology, Hungary","startDate":"2008-11","conditions":"Healthy Volunteers","enrollment":85},{"nctId":"NCT00434733","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Influenza","enrollment":4400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["adjuvanted influenza vaccine"],"phase":"marketed","status":"active","brandName":"Fluad Vaccine","genericName":"Fluad Vaccine","companyName":"David H. Canaday","companyId":"david-h-canaday","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The Fluad Vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It is used to study and potentially prevent influenza in older adults, as part of a broader research effort to analyze next-generation influenza vaccines in this demographic.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}